CD28 and neoplasm: CD8+ CD103+ CD39+ PD-1+ CD28- TRM cells, known for their higher anti-tumour cytokine production, may facilitate the recruitment of less-exhausted peripheral T-cells to the NSCLC tumour site, potentially improving their response to ICIs [266].